June 30, 2018 / 12:10 AM / Updated 10 hours ago AbbVie, AndroGel partner owe $448 million in antitrust case - U.S. judge Nate Raymond 2 Min Read
(Reuters) - A U.S. judge on Friday found that pharmaceutical company AbbVie Inc ( ABBV.N ) used sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from getting to market and ordered the drugmaker and its partner to pay $448 million.

Read the source article at Business News